Review of the novelties presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I);Revisión de las novedades presentadas en el XXVI Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

Revista de Neurologia

Volumn 52, Issue 4, 2011, Pages 227-238

  Fernández Fernández, Óscar ^a   Álvarez Cermeño, José C ^c   Arbizu Urdiain, Txomin ^d   Arroyo González, Rafael ^e   Arnal García, Carmen ^f   Casanova Estruch, Bonaventura ^g   Calles Hernández, M Carmen ^h   Coret Ferrer, Francisco ⁱ   Comabella, Manuel ^b   García Merino, Juan A ^j   De Las Heras, Virginia ^e   Izquierdo, Guillermo ^k   Meca Lallana, José E ^l   Muñoz García, Delicias ^m   Olascoaga, Javier ⁿ   Oreja Guevara, Celia ^o   Prieto, José M ^p   Rodríguez Antigüedad, Alfredo ^q   Tintoré, Mar ^b   Montalban, Xavier ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^m HOSPITAL XERAL CÍES   (Spain)

ⁿ HOSPITAL DONOSTIA   (Spain)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^q HOSPITAL DE BASURTO   (Spain)

more..

Author keywords

Diagnosis; ECTRIMS; Genetics; Multiple sclerosis; Progression

Indexed keywords

BETA INTERFERON; ESTROGEN RECEPTOR BETA; HLA ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; BIOLOGICAL MARKER;

AGING; ALLELE; DELAYED DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EPSTEIN BARR VIRUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SEX DIFFERENCE; VITAMIN D DEFICIENCY; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; ENVIRONMENT; EUROPE; FEMALE; GENETICS; LIFESTYLE; MALE; NERVE REGENERATION; ORGANIZATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VIRUS INFECTION;

BIOLOGICAL MARKERS; CONGRESSES AS TOPIC; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; ENVIRONMENT; EUROPE; FEMALE; HUMANS; LIFE STYLE; MALE; MULTIPLE SCLEROSIS; NERVE REGENERATION; VIRUS DISEASES;

EID: 79952261505     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5204.2010782     Document Type: Review

References (33)

1. Bentzen J, Thygesen LC, Flachs EM, Stenager E, Brønnum-Hansen H, Koch Henriksen N. Diagnostic delay in multiple sclerosis. Mult Scler 2010; 16: S7-39 [abstract 39].
2. Butzkueven H, Meyniel C, Spelman T, Izquierdo G, Grand'Maison F, Trojano M. MRI and CSF as predictors of time to relapse after CIS in neurological practice. Mult Scler 2010; 16: S7-39 [abstract 38].
3. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353-60. (Pubitemid 38745513)
4. Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci U S A 2007; 104: 14813-8. (Pubitemid 350003225)
5. Crawford DK, Mangiardi M, Song B, Patel R, Du S, Sofroniew MV, et al. Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain 2010; 133: 2999-3016.
6. Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 2010; 133: 1869-88.
7. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-32.
8. Graziano G, D'Onghia M, Lucchese G, Lepore V, Trojano M, on behalf of MSBase Registry Research Groups. Sex ratio of multiple sclerosis: a comparison of distribution and trend over 60 years among different countries. Mult Scler 2010; 16: S7-39 [abstract 122].
9. Sawcer S. The new MS gene list -whole genome association studies in MS. Mult Scler 2010; 16: S7-39 [abstract 31].
10. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-62.
11. Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, et al. Single nucleotide polymorphisms in HLA- and non-HLA genes predict the development of antibodies to interferonbeta therapy in patients with multiple sclerosis. Mult Scler 2010; 16: S7-39 [abstract 31].
12. Payseur BA, Place M, Weber JL. Linkage disequilibrium between STRPs and SNPs across the human genome. Am J Hum Genet 2008; 82: 1039-50.
13. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-89.
14. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66: 739-53.
15. Molnarfi N, Weber MS, Prod'homme T, Patarroyo JC, Linington C, Slavin AJ, et al. Myelin-specific B-cell receptor transgenic mice reveal role for B-cell APC function independent of antibodies in pathogenesis of CNS autoimmunity. Mult Scler 2010; 16: S7-39 [abstract 51].
16. Flugel A, Odoardi F, Nosov M, Kawakami N. Autoaggressive effector T cells in the course of experimental autoimmune encephalomyelitis visualized in the light of two-photon microscopy. J Neuroimmunol 2007; 191: 86-97. (Pubitemid 350061003)
17. Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68: 369-83.
18. Reali C, Magliozzi R, Kirresh A, Howell OW, Reynolds R. The relationship between meningeal inflammation and spinal cord pathology in multiple sclerosis. Mult Scler 2010; 16: S7-39 [abstract 90].
19. Witte ME, Drexhage J, Gerritsen WH, Reijerkerk A, De Vries HE, Van der Valk P. Mitochondrial antioxidants: putative targets for slowing down disease progression. Mult Scler 2010; 16: S7-39 [abstract 91].
20. Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009; 29: 11511-22.
21. Zujovic V, Thibaud J, Bachelin C, Vidal M, Coulpier F, Charnay P, et al. Boundary cap cells are highly competitive for CNS remyelination: fast migration and efficient differentiation in PNS and CNS myelin-forming cells. Stem Cells 2010; 28: 470-9.
22. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57: 1192-203.
23. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17: 1799-803.
24. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010; 16: 503-10.
25. Fisniku LK. MRI as a predictive tool in MS. Mult Scler 2010; 16: S7-39 [abstract 115].
26. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247-54.
27. Ferré JC, Wiest-Daesslé N, Ranjeva JP, Pelletier J, Berry I, Clanet M, et al. Longitudinal follow-up of USPIO enhanced lesions of clinically isolated syndrome patients. Mult Scler 2010; 16: S41-196 [abstract P351].
28. Zayed N, Costello F, Trufyn J, Smith M, Goodyear B. Resting state fMRI determines cortical contribution to recovery from optic neuritis. Mult Scler 2010; 16: S41-196 [abstract P339].
29. Begum-Haque S, Sharma A, Kasper IR, Foureau DM, Mielcarz DW, et al. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol 2008; 204: 58-65.
30. Dhib-Jalbut S, Chen M, Said A, Zhan M, Johnson KP, Martin R. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 2003; 140: 163-71. (Pubitemid 36836102)
31. Sundstrom P. Evidence for virus infections in the presymptomatic stage of MS. Mult Scler 2010; 16: S7-39 [abstract 93].
32. Baarnhielm M, Hedström A, Kockum I, Sundqvist E, Gustafsson S, Olsson T, et al. Multiple sclerosis is associated with low previous ultraviolet radiation exposure and low levels of current vitamin D: no interaction with HLA complex genes. Mult Scler 2010; 16: S7-39 [abstract 55].
33. Kimlin MG, Olds WJ, Moore MR. Location and vitamin D synthesis: is the hypothesis validated by geophysical data? J Photochem Photobiol B 2007; 86: 234-9.